

# Yushen Qian, M.D.

## **EDUCATION**

<b>Duke University</b> B.S. in Chemistry with Concentration in Biochemistry	Durham, NC	09/01/2005 – 05/31/2009
<b>University of Michigan Medical School</b> M.D. degree conferred on May 17, 2013	Ann Arbor, MI	09/01/2009 – 05/31/2013
<b>Oakwood Hospital</b> PGY-1 Transition Year Internship	Dearborn, MI	07/01/2013 – 06/30/2014
<b>Stanford University School of Medicine</b> Department of Radiation Oncology, Stanford Healthcare Resident Physician (PGY II – V), Chief Resident (PGY IV & V)	Stanford, CA	07/01/2014 – 06/30/2018

## **PROFESSIONAL EXPERIENCE**

<b>Southern California Permanente Medical Group</b> Department of Radiation Oncology, Los Angeles and Ontario Medical Centers	Los Angeles, CA	08/08/2018 – present
<ul style="list-style-type: none"><li>• Associate Physician (Partnership expected August 2021)</li><li>• Ontario Medical Center Head &amp; Neck Disease Site Co-Lead</li></ul>		

## **LICENSURE**

<b>USMLE Step 1</b>		2011
<b>USMLE Step 2</b>		2012
<b>USMLE Step 3</b>		2013
<b>Medical Board of California (A132191)</b>		2014
<b>DEA Certification</b>		2014
<b>American Board of Radiology</b>		
Physics and Radiation Biology	Pass	2017
Written Clinical	Pass	2018
Oral Clinical	Pass	2019
Board Certification		2019

## **HONORS AND AWARDS**

National Merit Scholar	2004
Robert C. Byrd Scholar	2004
<i>Phi Beta Kappa</i> Inductee	2008
Xerox Technical Minority Scholar	2008
<i>Magna Cum Laude</i> with Distinction in Chemistry	2009
Dean's Merit Scholarship	2009
Conquer Cancer Foundation of ASCO Merit Award (Palliative Care in Oncology Symposium)	2015
AACR Scholar-in-Training Award (San Antonio Breast Cancer Symposium)	2015
Henry Kaplan Research Fund Recipient	2015
Malcolm A. Bagshaw Research Symposium Best Research Award	2017
NCCN Oncology Fellow	2017
ASTRO Annual Meeting Oral Presentation	2017, 2018
ARS 100 <sup>th</sup> Annual Meeting Travel Grant, Best Poster Award, Oral Presentation	2018
ASTRO 60 <sup>th</sup> Annual Meeting Abstract Award	2018

## **SCHOLARLY PUBLICATIONS**

### **Peer Reviewed Publications (Original Research) (\*co-first authorships)**

1. Capp C, **Qian Y\***, Sage H, Huber H, Hsieh TS. "Separate and Combined Biochemical Activities of the Subunits of a Naturally Split Reverse Gyrase." *Journal of Biological Chemistry*. 2010; 285(51): 39637-45.  
[PMID: 20929866](#)
2. **Qian Y**, Feng FY, Halverson S, Blas K, Sandler HM, Hamstra, DA. "The Percent of Positive Biopsy Cores Improves Prediction of Prostate Cancer-Specific Death in Patients Treated with Dose-Escalated Radiotherapy." *International Journal of Radiation Oncology\*Biological\*Physics*. 2011; 81(3): e135-42.  
[PMID: 21345617](#)
3. Parsels LA, **Qian Y**, Tanska DM, Gross M, Zhao L, Hassan MC, Arumugarajah S, Parsels JD, Hylander-Gans L, Simeone DM, Morosini D, Brown JL, Zabludoff SD, Maybaum J, Lawrence TS, Morgan MA. "Assessment of Chk1 Phosphorylation as a Pharmacodynamic Biomarker of Chk1 Inhibition." *Clinical Cancer Research*. 2011; 17(11): 3706-15.  
[PMID: 21482692](#)
4. Feng FY, **Qian Y\***, Stenmark MH, Halverson S, Blas K, Vance S, Sandler HM, Hamstra DA. "Perineural Invasion Predicts Increased Recurrence, Metastasis, and Death from Prostate Cancer Following Treatment with Dose-Escalated Radiation Therapy." *International Journal of Radiation Oncology\*Biological\*Physics*. 2011; 81(4): e361-7.  
[PMID: 21820250](#)
5. Engelke CG, Parsels LA, **Qian Y**, Zhang Q, Karnak D, Robertson JR, Tanska DM, Wei D, Davis MA, Parsels JD, Zhao L, Greenson JK, Lawrence TS, Maybaum J, Morgan MA. "Sensitization of pancreatic cancer to chemoradiation by the Chk1 inhibitor MK8776." *Clinical Cancer Res*. 2013; 19(16): 4412-21.  
[PMID: 23804422](#)
6. Durkee BY, **Qian Y\***, Pollom EL, King MT, Dudley SA, Shaffer JL, Chang DT, Gibbs IC, Goldhaber-Fiebert JD, Horst KC. "Cost-Effectiveness of Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer." *Journal of Clinical Oncology*. 2016; 34(9): 902-9.  
[PMID: 26351332](#) (Included in: Best of JCO 2016 Annual Meeting Edition)
7. Chaudhuri AA, Binkley MS, Aggarwal S, **Qian Y**, Carter JN, Shah R, Loo BW. "Severe Chest Wall Toxicity from Cryoablation in the Setting of Prior Stereotactic Ablative Radiotherapy." *Cureus*. 2016; 8(2): e477.  
[PMID: 27004154](#)
8. Chaudhuri AA, Binkley MS, Rigdon J, Carter JN, Aggarwal S, Dudley SA, **Qian Y**, Kumar KA, Hara WY, Gensheimer M, Nair VS, Maxim PG, Shultz DB, Bush K, Trakul N, Le QT, Diehn M, Loo BW, Guo HH. "Pre-treatment non-target lung FDG-PET uptake predicts symptomatic radiation pneumonitis following Stereotactic Ablative Radiotherapy (SABR)." *Radiotherapy Oncology*. 2016; 119(3): 454-60.  
[PMID: 27267049](#)
9. Pollom EL, **Qian Y\***, Durkee BY, von Eyben R, Maxim PG, Shultz DB, Gensheimer M, Diehn M, Loo BW. "Hypofractionated Intensity-Modulated Radiotherapy for Patients with Non-Small Cell Lung Cancer." *Clinical Lung Cancer*. 2016; S1525-7304(16): 30140-1.  
[PMID: 27378172](#)
10. **Qian Y**, Zhu H, Pollom EL, Durkee BY, Chaudhuri AA, Gensheimer MF, Diehn M, Shultz DB, Loo BW. "Sinoatrial Node Toxicity after Stereotactic Ablative Radiotherapy to Lung Tumors." *Practical Radiation Oncology*. 2017; 7(6): e525-9.

[PMID: 28669706](#)

11. **Qian Y**, Maruyama S, Kim H, Pollom EL, Kumar KA, Chin AL, Harris JP, Chang DT, Pitt A, Bendavid E, Owens DK, Durkee BY, Soltys SG. “Cost-Effectiveness of Radiation and Chemotherapy for High-Risk Low-Grade Glioma.” *Neuro-Oncology*. 2017; 19(12): 1651-60.

[PMID: 28666368](#)

12. **Qian Y**, Pollom EL, Nwachukwu C, Seiger K, von Eyben E, Folkins AK, Kidd E. “Extent of Lymphovascular Space Invasion May Predict Lymph Node Metastasis in Uterine Serous Carcinoma.” *Gynecologic Oncology*. 2017; 147(1):24-29.

[PMID: 28709703](#)

13. Chin AL, Pollom EL, **Qian Y**, Koong AC, Chang DT. “The Impact of Intensity-Modulated Radiotherapy on Health Care Costs Among Patients with Anal Squamous Cell Carcinoma.” *Journal of Oncology Practice*. 2017; 13(12): e992-1001.

[PMID: 29035618](#)

14. **Qian Y**, von Eyben R, Liu Y, Chin F, Miao Z, Apte S, Carter JN, Binkley MS, Pollom EL, Harris JP, Prionas ND, Kissel M, Simmons A, Diehn M, Shultz DB, Brown JM, Koong AC, Graves T, Loo BW. “18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated with Highly Conformal Radiation Therapy.” *International Journal of Radiation Oncology\*Biological\*Physics*. 2018; 102(4):1183-1192.

[PMID: 29859786](#)

15. Pollom EL, **Qian Y**, Chin AL, Dirbas FM, Asch SM, Kurian AW, Horst KC, Tsai CJ. Rising rates of bilateral mastectomy with reconstruction following neoadjuvant chemotherapy. *International Journal of Cancer*. 2018; 143(12):3262-3272.

[PMID: 29992582](#)

16. Harris JP, Nwachukwu CR, **Qian Y**, Pollom EL, Loo BW, Das M, Diehn M. “Invasive Nodal Evaluation Prior to Stereotactic Ablative Radiation for Non-Small Cell Lung Cancer.” *Lung Cancer*. 2018;124:76-85.

[PMID: 30268484](#)

17. Grade M, Koenig J, **Qian Y**, Sandhu N, Liu Y, von Eyben R, Knox SK, Dudley SA. “Outcomes and characteristics of patients treated with emergent palliative radiotherapy.” *Practical Radiation Oncology*. 2018; 9(2):e203-e209

[PMID: 30529795](#)

18. Harris JP, Saraswathula A, Kaplun B, **Qian Y**, Chan KCA, Chan ATC, Le QT, Owens DK, Goldhaber-Fiebert JD, Pollom EL. “Cost-Effectiveness of Screening for Nasopharyngeal Carcinoma for Asian-American Men in the US.” *Otolaryngology-Head and Neck Surgery*. 2019; 161(1):82-90.

[PMID: 30832545](#)

19. Wu J, Gensheimer MF, Zhang N, Han F, Liang R, **Qian Y**, Zhang C, Fischbein N, Pollom EL, Beadle B, Le QT, Li R. “Integrating tumor and nodal imaging characteristics at baseline and mid-treatment CT scans to predict distant metastasis in oropharyngeal cancer treated with concurrent chemoradiotherapy.” *International Journal of Radiation Oncology\*Biological\*Physics*. 2019; 104(4):942-952.

[PMID: 30940529](#)

20. Weil C, **Qian Y\***, von Eyben R, Daadi SE, Corbelli KS, Rosenberg SA, Advani RH, Hoppe RT. “Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation.” *Leukemia & Lymphoma*. 2020; 61(10):2428-2434.

[PMID: 32476541](#)

### Peer Reviewed Publications (Other)

1. **Qian Y**, Chapman C, Chapman M. "The Face Behind the Illness." Featured in A.K. Kumagai, "Acts of Interpretation: A Philosophical Approach to Using Creative Arts in Medical Education." *Academic Medicine* 2012; 87(8): 1138-44.
2. Durkee BY, **Qian Y**\*, Goldhaber-Fiebert JD, Horst KC. "Reply to R. Colomer et al." *Journal of Clinical Oncology*. 2016; 34(26): 3227-8.  
[PMID: 27432936](#)
3. **Qian Y**, Kumar KA, Dudley SA, Koong AC, Chang DT. "Radiation Therapy for Colorectal Liver Metastases." *Current Colorectal Cancer Reports*. 2017; 13(3): 240-9.  
[Manuscript at SpringerLink](#)
4. **Qian Y**, Chin AL, Toesca DAS, Koong AC, Chang DT. "Nonoperative Management of Rectal Cancer: A Modern Perspective." *Oncology*. 2017; 31(10): e13-22.  
[PMID: 29083469](#)

### Book Chapters

1. Pollom EL, **Qian Y**, Koenig J, Koong AC, Chang DT. "*Radiation Therapy for Hepatocellular Carcinoma: Clinical Data*." Chapter 14. "Radiation Therapy for Liver Tumors" by Jeffrey Meyer & Tracey Schefter, Springer International Publishing. 2017; 179-198.  
[ISBN 978-3-319-54531-8](#)
2. **Qian Y**, Weiner JP, Moding E, Kovalchuk N, Koong AC, Hong TS, Chang DT. "*Liver*." "Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy" by Dwight Heron, Saiful Huq, and Joseph Herman. DemosMedical, Springer Publishing Company. 2018.

### Digital Publication

1. **Qian Y**, Chang DT. "*Video 15.1 Treatment Simulation and Planning for Liver Tumors*." "Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy" by Dwight Heron, Saiful Huq, and Joseph Herman. DemosMedical, Springer Publishing Company. 2018.

### Oral Presentations

1. **Qian Y**, Maruyama S, Kim H, et al. "Cost-Effectiveness of Radiation and Chemotherapy for High-Risk Low-Grade Glioma." ASTRO Annual Meeting. San Diego, CA, September 2017.
2. **Qian Y**, von Eyben R, Liu Y, et al. "18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated with Conformal Radiation Therapy." ARS 100<sup>th</sup> Annual Meeting. Orlando, FL, May 2018.
3. **Qian Y**, von Eyben R, Liu Y, et al. "18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated with Conformal Radiation Therapy." ASTRO Annual Meeting. San Antonio, TX, October 2018.  
*\*also selected for Basic/Translational Science Award in the Junior Investigator Radiation Physics category*
4. Weil C, **Qian Y**\*, von Eyben R, et al. "The Outcomes of Patients with Unfavorable Stage I-II Classic Hodgkin Lymphoma Treated with Stanford V Chemotherapy and Limited Irradiation." ASTRO Annual Meeting. San Antonio, TX, October 2018. [Poster Discussion Session]  
*(\*co-first authorship)*

## Presented Abstracts

1. **Qian Y**, Parsels LA, Lawrence TS, et al. "Combination Therapy of Gemcitabine and Chk1/2 inhibitor, AZD7762, in Pancreatic Cancer: Preclinical Optimization of Scheduling and Biomarkers." University of Michigan Cancer Center Fall Research Symposium. Ann Arbor, MI, November 2010.
2. **Qian Y**, Parsels LA, Lawrence TS, et al. "Preclinical Optimization of Chk1/2 Inhibitor, AZD7762 and Gemcitabine: Biomarkers and Scheduling in Pancreatic Cancer." University of Michigan Summer Biomedical Research Program Symposium. Ann Arbor, MI, November 2010.
3. **Qian Y**, Halverson S, Blas K, et al. "Use of Percent Positive Biopsy Cores to Predict Prostate Cancer-Specific Death in Patients Treated with Dose-Escalated Radiotherapy." American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. Orlando, FL, February 2011.
4. Kapadia NS, **Qian Y**, Stenmark MH, et al. "Perineural Invasion Predicts for Increased Recurrence, Metastasis, and Death from Prostate Cancer Following Treatment with Dose-Escalated Radiation Therapy." American Society for Radiation Oncology (ASTRO) Annual Meeting. Miami, FL, October 2011.
5. **Qian Y**, Durkee BY, Pollom EL, et al. "Cost-Effectiveness of Pertuzumab in HER2+ Metastatic Breast Cancer." San Antonio Breast Cancer Symposium. San Antonio, TX, December 2015.
6. Dudley SA, **Qian Y**, Chaudhuri AA, et al. "Survival Comparison of Patients Treated with One versus Five Fraction Palliative Radiotherapy." Palliative Care in Oncology Symposium. Boston, MA, October 2015.
7. Kumar KA, Choi C, White EC, et al. "Spinal Stereotactic Radiosurgery: Dosimetric Correlates of Tumor Control." ASTRO Annual Meeting. San Antonio, TX, October 2015.
8. Dudley SA, **Qian Y**, Horst KC. "Supraclavicular Nodal Involvement in Breast Cancer: How and When Should We Adapt the RTOG Atlas Guidelines?" ASTRO Annual Meeting. San Antonio, TX, October 2015.
9. **Qian Y**, Dudley SA, Durkee BD, et al. "Fractionation of Palliative Radiotherapy in Metastatic Breast Cancer - Selection and Survival." Palliative Care in Oncology Symposium. Boston, MA, October 2015.
10. **Qian Y**, Carter J, Von Eyben R, et al. "Imaging of Hypoxia in Early Stage Lung Cancer Treated with SABR." Stanford Cancer Institute Member's Retreat Symposium. Stanford, CA, April 2016.
11. **Qian Y**, Aggarwal S, Dudley SA, et al. "Socioeconomic Resources and Survival in Patients with Metastatic Breast Cancer Treated with Palliative Radiotherapy." ASCO Annual Meeting (Publication Only). Chicago, IL, June 2016.
12. Dudley SA, **Qian Y**, Aggarwal S, et al. "Comparison of Survival by Different Palliative Radiation Therapy Fractionation Schedules." ASTRO Annual Meeting. Boston, MA, September 2016.
13. **Qian Y**, Aggarwal S, Dudley SA, et al. "Fractionation of Palliative Radiotherapy in Metastatic Breast Cancer - Selection and Survival." ASTRO Annual Meeting. Boston, MA, September 2016.
14. **Qian Y**, Pollom EL, Durkee BY, et al. "Patterns of Failure After Hypofractionated Intensity-Modulated Radiotherapy for Patients with Non-Small Cell Lung Cancer." ASTRO Annual Meeting. Boston, MA, September 2016.
15. **Qian Y**, Dudley SA, Kumar KK, et al. "Sinoatrial Node Dysfunction after Stereotactic Ablative Therapy in the Chest." ASCO Cancer Survivorship Symposium. San Diego, CA, January 2017.
16. **Qian Y**, Pollom EL, Nwachukwu C, et al. "Extent of Lymphovascular Space Invasion Predicts for

Nodal Involvement in Uterine Serous Carcinoma.” ASTRO Annual Meeting. San Diego, CA, September 2017.

17. **Qian Y**, von Eyben R, Liu Y, et al. “18F-EF5 PET-based Imageable Hypoxia Predicts Local Recurrence in Tumors Treated with Conformal Radiation Therapy.” ARS 100<sup>th</sup> Annual Meeting. Orlando, FL, May 2018.

*\*Selected for Travel Grant*

18. **Qian Y**, Maruyama S, Kim H, et al. “Cost-Effectiveness of Radiation and Chemotherapy for High-Risk Low-Grade Glioma.” ARS 100<sup>th</sup> Annual Meeting. Orlando, FL, May 2018.

*\*Selected for Best Poster Award*

## **PUBLIC AND PROFESSIONAL SERVICE**

### **Stanford Healthcare, Department of Radiation Oncology**

Program Evaluation Committee, Resident Representative	2015-2016
Resident Wellness Committee	2015-2017
Varian Scholar Literature Analyst	2015-2018
Stanford Hospital Chief Resident Council	2016-2018
ASTRO Payer Relations Subcommittee	2017-2018
Supervising Physician for Contrast-Enhanced Imaging Studies	2017-2018
Special Review Committee, Chief Resident Representative	2018

### **Kaiser Permanente, Department of Radiation Oncology**

Varian ARIA/Eclipse Software Implementation Physician Co-Lead	2020
---	------

## **TEACHING EXPERIENCE**

### **Lectures to Residents**

#### **Stanford Healthcare, Department of Radiation Oncology**

Management and Overview of Seminoma	2014
Regional Nodal Management and Breast Radiotherapy in the Modern Era	2016
Nasopharyngeal Cancer Case Discussion	2016
Esophageal and Gastric Cancers Case Discussion	2016
Brain and Spine Metastases Case Discussion	2016
Introduction Prostate and Head and Neck Cancers for Medical Physicists	2016
Management of High-Grade Glioma	2016
Techniques in Craniospinal Radiation	2017
Genitourinary Cancers Question Review	2017
Gynecological Cancers Question Review	2017
Management of Larynx and Hypopharynx Cancers	2017
Management of Bladder and Ureteral Cancers	2017

#### **Kaiser Permanente, Department of Radiation Oncology**

Management of Low-Grade Glioma	2019
Management of Nasopharyngeal and Oropharyngeal Cancers	2020